Nykode Therapeutics : Final Results from the Phase 2 VB-C-02 trial – presentation

VB10.16 Final Phase 2 data readout - 12 month treatment follow up

April 19 2023

Forward-looking statement

This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate.

A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Nykode Therapeutics | VB C-02 Data Presentation | Non-confidential

2

Today's presenters

MICHAEL ENGSIG		AGNETE FREDRIKSEN		KLAUS EDVARDSEN
Chief Executive Officer		Chief Business Officer & Co-founder		Chief Development Officer

Nykode Therapeutics | VB C-02 Data Presentation | Non-Confidential

3

Positive results from VB C-02 - Executive Summary

Durable anti-tumor activity

• VB10.16 in combination with atezolizumab showed sustained overall survival and durable responses: mOS1 16.9 months, mPFS2 4.1 months and mDOR3 17.1 months
• In PD-L1+ patients, this was further enhanced with mOS not reached (25+ months) and mPFS 6.3 months

Enhanced clinical activity over CPI4 monotherapy / existing SoC5

• Overall, ORR6 19% and a high DCR7 of 60% were achieved
• In PD-L1+ patients: ORR 29% and DCR 75%

Safety data

• VB10.16 in combination with atezolizumab was generally well-tolerated and had a tolerability profile consistent with known CPI monotherapy
  Correlation with immune responses
• HPV16-specificIFN-g T cell responses were significantly correlated with clinical activity

Best responses seen in patient group selected for future trials

• PD-L1+and 1 prior line of systemic anticancer treatment: mPFS 16.9 months, mOS not reached (25+ months), ORR 40% and DCR 80%

Together these findings indicate a potentially differentiated and lasting clinical activity profile for VB10.16 in

combination with atezolizumab compared to checkpoint inhibitor monotherapy8

Note: 1 mOS: median overall survival; 2 mPFS: median progression free survival; 3 mDOR : median duration of response; 4 CPI: checkpoint inhibitors; 5 SoC: standard of care; 6 ORR: overall response rate; 7 DCR: disease control rate;

8:1Chung et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol 2019; Tewari et al. Survival with cemiplimab in recurrent cervical cancer. N Engl J Med 2022; Tabernero et al. Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers. ESMO Open. 2022.

Nykode Therapeutics | VB C-02 Data Presentation | Non-confidential

4

Global leader in antigen presenting cell (APC)- targeted immunotherapy technology

NYKODE THERAPEUTICS (NYKD-OL, MKT CAP ~$700M)

Proprietary immunotherapies targeting antigens to Antigen-Presenting Cell (APC) and generating strong CD8 killer T cell responses correlated with clinical responses in solid tumors

Modular, versatile platform

• Easily incorporate new antigens and adapt to new diseases across oncology, infectious diseases and autoimmunity

Rapidly advancing wholly owned lead asset, VB10.16, immunotherapy for HPV16+ cancers

• Reporting final data from C-02 with focus on durability today
• Potentially registrational study in advanced cervical cancer to initiate 2023
• Dose escalation study with KEYTRUDA®1 in head and neck cancer to initiate 1H2023

Strategic partnerships to advance clinical programs and commercialize assets worldwide2

Well-capitalized with a cash position of $206m at December 31, 2022

1. Note: KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
2. Note: Genentech has an exclusive license to VB10.NEO. Collaboration and license to 5 programs with Regeneron. Collaboration and license with Adaptive Biotechnologies on SARS-CoV-2 T cell vaccine. Roche supplies atezolizumab; . Merck (MSD) supplies pembrolizumab

Nykode Therapeutics | VB C-02 Data Presentation | Non-confidential

5